Iaso Therapeutics, Inc.
Iaso Therapeutics is dedicated to developing next generation vaccines to enhance human health and treat diseases. It focuses on innovative vaccine technologies, including a proprietary mutant bacteriophage Qβ platform, to address infectious diseases and cancer. The company aims to translate cutting-edge research into real-world health solutions, leveraging collaborations with Michigan State University and support from various grants and investments.
Industries
Nr. of Employees
small (1-50)
Iaso Therapeutics, Inc.
East Lansing, Michigan, United States, North America
Products
Mutant bacteriophage Qβ virus-like particle (VLP) carrier platform
A VLP-based carrier platform engineered to enhance antibody responses when conjugated to subunit antigens; intended for use in conjugate vaccine development.
Mutant bacteriophage Qβ virus-like particle (VLP) carrier platform
A VLP-based carrier platform engineered to enhance antibody responses when conjugated to subunit antigens; intended for use in conjugate vaccine development.
Services
Co-development partnerships and sublicensing
Collaborative development agreements and sublicenses to leverage the VLP carrier platform in partner vaccine programs.
Preclinical vaccine development and immunogenicity testing
Design and execution of preclinical studies including antigen conjugation, formulation, animal immunizations, and antibody readouts to assess vaccine candidates.
Co-development partnerships and sublicensing
Collaborative development agreements and sublicenses to leverage the VLP carrier platform in partner vaccine programs.
Preclinical vaccine development and immunogenicity testing
Design and execution of preclinical studies including antigen conjugation, formulation, animal immunizations, and antibody readouts to assess vaccine candidates.
Expertise Areas
- Next-generation vaccine platform development
- Conjugate vaccine chemistry
- Glyco-chemistry and complex glycan synthesis
- Preclinical immunology and animal models
Key Technologies
- Virus-like particle (VLP) platforms
- Conjugate antigen chemistry
- Complex glycan synthesis
- Nanoparticle vaccine delivery